IRLAB Has Administered the First Dose in a Phase I Clinical Trial with the Drug Candidate IRL757

IRLAB Therapeutics AB announced that dosing has been initiated in a Phase I study of the drug candidate IRL757. IRL757 has been shown in preclinical disease models to counteract apathy – a condition that impairs the quality of life for millions of people with Parkinson’s disease and other CNS diseases.